Jan 11, 2021 / 07:50PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. And we're continuing the health care conference today with Nektar Therapeutics. I'm joined by the company's CEO, Howard Robin.
And unlike typically at the conference where we would go across the hall for question and answers, this session is going to move seamlessly into a Q&A session once Howard is done with the presentation. And if you use the blue ask-the-question button online, you can send questions to me via the portal, and I can ask them to management in our virtual breakout session.
So with that, let me pass it over to Howard.
Howard W. Robin - Nektar Therapeutics - CEO, President & Director
Okay. Thank you, Jessica, for inviting us to speak again at the JPMorgan Healthcare Conference and kick off the New Year.
Before I get started, I will show you a slide on forward-looking statements. So please go to the next slide. And I'm going to be
Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual) Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers